

Cover image: Comparison of health-related quality of life (HRQoL) across indications. (A) Mean short form 36 (SF-36) scores for patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or psoriasis (PsO) at baseline and average age and gender-matched norms for all indications are shown. (B) Mean SF-36 values at endpoint are shown for patients with RA (etanercept (ETN) plus methotrexate (MTX)-treated patients at week 52), PsA (etanercept-treated patients at week 24), and psoriasis (etanercept 50 mg twice a week (BIW)-treated patients at week 12) with average age and gender-matched norms for all indications. p 1148.

## Editor

Tore K Kvien

## Associate Editors

Francis Berenbaum  
Hans Bijlsma  
David Pisetsky  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes

## Editorial office

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 9.082

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2012 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Newgen and printed in the UK on acid-free paper from sustainable forests by Buxton Press, Buxton

Annals of the Rheumatic Diseases (ISSN: 0003-4967) is published monthly by BMJ Publishing Group and is distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

## Editorial

- 1107** The importance of patient participation in measuring rheumatoid arthritis flares  
*C O Bingham III, R Ahen, M P de Wit*

## Clinical and epidemiological research

- 1110** A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: The 'FLARE' instrument  
*J-M Berthelot, M De Bandt, J Morel, F Benatig, A Constantini, P Gaudin, X Le Loet, J-F Maillefer, O Meyer, T Pham, A Saraux, E Solau-Gervais, E Spitz, D Wendling, B Faurel, F Guillemin, on behalf of the STPR group of the French Society of Rheumatology*

- 1117** Investigation of rheumatoid arthritis susceptibility loci in juvenile idiopathic arthritis confirms high degree of overlap  
*A Hinks, J Cobb, M Sudman, S Eyre, P Martin, E Flynn, J Packham, Childhood Arthritis Prospective Study (CAPS),\* UK RA Genetics (UKRAG) Consortium,\* British Society of Paediatric and Adolescent Rheumatology (BSPAR) Study Group,\* A Barton, J Worthington, C D Langefeld, D N Glass, S D Thompson, W Thomson*

- 1122** Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting  
*E B Nordal, M Zak, K Aalto, L Bernison, A Fasth, T Herlin, P Lahdenne, S Nielsen, S Peltoniemi, B Straume, M Rygg*

- 1128** Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis  
*W G Dixon, M Abrahamowicz, M-E Beauchamp, D W Ray, S Bernatsky, S Suissa, M-P Sylvestre*

- 1134** A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry  
*J D Greenberg, G Reed, D Decktor, L Harrold, D Furst, A Gibofsky, R DeHoratius, M Kishimoto, J M Kremer, on behalf of the CORRONA Investigators*

- 1143** Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment  
*V Strand, V Sharp, A S Koenig, G Parke, Y Shi, B Wang, D J Zack, D Fiorentino*

- 1151** Aortic stiffness is increased in polymyalgia rheumatica and improves after steroid treatment  
*G Schillaci, E Baroloni, G Pucci, M Piro, L Settini, A Alunno, R Gerli, E Mannarino*

- 1157** Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis  
*C Charles-Schoeman, Y Y Lee, V Grijalva, S Amjadi, J FitzGerald, V K Ranganath, M Taylor, M McMahon, H E Paulus, S T Reddy*

- 1163** Fibrinogen and factor XIII A-subunit genotypes interactively influence C-reactive protein levels during inflammation  
*B Hoppe, T Häupl, A Skapenko, S Ziemer, R Tauber, A Salama, H Schulze-Koops, G-R Burmester, T Dörner*

- 1170** Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography  
*S Prieto-González, P Arguís, A García-Martínez, G Espigol-Frigolé, I Tavera-Bahillo, M Buitosa, M Sánchez, J Hernández-Rodríguez, J M Grau, M C Cid*

- 1177** An International registry on Autoinflammatory diseases: the Eurofever experience  
*N Toplak, J Frenkel, S Ozen, H J Lachmann, P Woo, I Koné-Paut, F De Benedetti, B Neven, M Hofer, P Dolezalova, J Kümmerle-Deschner, I Touitou, V Hentgen, A Simon, H Girschick, C Rose, C Wouters, R Vesely, J Arostegui, S Stojanov, H Ozgöden, A Martini, N Ruperto, M Gattorno for the Paediatric Rheumatology International Trials Organisation (PRINTO), Eurotraps and Eurofever Projects*

- 1183** A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate  
*P Mease, V Strand, L Shalamberidze, A Dimic, T Raskina, L-A Xu, Y Liu, J Smith*

- 1190** Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index  
*D Aletaha, J Martinez-Avila, T K Kvien, J S Smolen*

- 1197** *IRF5* polymorphism predicts prognosis in patients with systemic sclerosis  
*R Sharif, M D Mayes, F K Tan, O Y Gorlova, L K Hummers, A A Shah, D E Furst, D Khanna, J Martin, L Bossini-Castillo, E B Gonzalez, J Ying, H T Draeger, S K Agarwal, J D Reveille, F C Arnett, F M Wigley, S Assassi*

- 1203** Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study  
*E V Arkeba, M Neovius, J K Joellson, J F Simard, R F van Vollenhoven*

- 1207** The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study  
*U Kiltz, X Baraliakos, P Karakostas, M Igelmann, L Kalthoff, C Link, D Krause, E Schmitz-Bortz, M Flörecke, M Bollow, J Braun*

## MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtl>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

[www.publicationethics.org.uk](http://www.publicationethics.org.uk)




When you have finished with this please recycle it

**1212** Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial  
*I-H Song, C E Althoff, H Haibel, K-G A Hermann, D Poddubnyy, J Listing, A Weiß, S Djacenko, G R Burmester, M Bohl-Bühler, B Freundlich, M Rudwaleit, J Sieper*

**1216** Coexistence of hypothyroidism with inflammatory arthritis is associated with cardiovascular disease in women  
*H G Raterman, M M J Nielsen, M J L Peters, R A Verheij, M T Nurmohamed, F G Schellevis*

---

## Basic and translational research

**1219** Fine mapping and conditional analysis identify a new mutation in the autoimmunity susceptibility gene BLK that leads to reduced half-life of the BLK protein  
 *A M Delgado-Vega, M G Dozmorov, M B Quirós, Y-Y Wu, B Martínez-García, S V Kozyrev, J Frostegård, L Truedsson, E de Ramón, M F González-Escribano, N Ortego-Centeno, B A Pons-Estel, S D'Alfonso, G D Sebastiani, T Witte, B R Lauverys, E Endreffy, L Kovács, C Vasconcelos, B M da Silva, J D Wren, J Martin, C Castillejo-López, M E Alarcón-Riquelme*

**1227** Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions  
*A Mathian, C Parizot, K Dorgham, S Trad, L Arnaud, M Larsen, M Miyara, M Hié, J-C Piette, C Frances, H Yssel, Z Amoura, G Gorochov*

**1235** Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis  
*K Khan, S Xu, S Nihtyanova, E Derrett-Smith, D Abraham, C P Denton, V H Ong*

**1243** Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort  
*J-E Gotenberg, J-M Dayer, C Lukas, B Ducot, G Chiochia, A Cantagrel, A Saraux, P Roux-Lombard, X Mariette*

**1249** Decreased levels of nucleotide pyrophosphatase phosphodiesterase 1 are associated with cartilage calcification in osteoarthritis and trigger osteoarthritic changes in mice  
*J Bertrand, Y Nitschke, M Fuerst, S Hermann, M Schäfers, J Sherwood, G Nalesso, W Ruether, F Rutsch, F Dell'Accio, T Pap*

**1254** Increased type II deiodinase protein in OA-affected cartilage and allelic imbalance of OA risk polymorphism rs225014 at DIO2 in human OA joint tissues  
*S D Bos, J V M G Bovée, B J Duijnisveld, E V A Raine, W J Dalen, Y M Ramos, R van der Breggen, R G H H Nelissen, P E Slagboom, J Loughlin, I Meulenbelt*

---

## Letters

**1259** Association of *UBE2L3* polymorphisms with diffuse cutaneous systemic sclerosis in a Japanese population  
*N Hasebe, A Kawasaki, I Ito, M Kawamoto, M Hasegawa, M Fujimoto, H Furukawa, S Tohma, T Sumida, K Takehara, S Sato, Y Kawaguchi, N Tsuchiya*

**1260** Synovial synoviolin in relation to response to TNF blockade in patients with rheumatoid arthritis and psoriatic arthritis  
*R Klaasen, C A Wijbrandts, A W van Kuijk, D Pots, D M Gerlag, P P Tak*

**1262** Rituximab therapy for chronic periaortitis  
*F Mariati, D Corradi, A Versari, M Casali, M L Urban, C Buzio, A Vaglio*

---

## Miscellaneous

**1264** Corrections